AU3136293A - Pharmaceutical tablet with pvp having an enhanced drug dissolution rate - Google Patents

Pharmaceutical tablet with pvp having an enhanced drug dissolution rate

Info

Publication number
AU3136293A
AU3136293A AU31362/93A AU3136293A AU3136293A AU 3136293 A AU3136293 A AU 3136293A AU 31362/93 A AU31362/93 A AU 31362/93A AU 3136293 A AU3136293 A AU 3136293A AU 3136293 A AU3136293 A AU 3136293A
Authority
AU
Australia
Prior art keywords
pvp
dissolution rate
pharmaceutical tablet
drug dissolution
enhanced drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU31362/93A
Other languages
English (en)
Inventor
Ratan K. Chaudhuri
Jui-Chang Chuang
Rama K Haldar
Dinesh K Jaiswal
Robert B. Login
Mohammed Tazi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ISP Investments LLC
Original Assignee
ISP Investments LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/796,999 external-priority patent/US5262171A/en
Application filed by ISP Investments LLC filed Critical ISP Investments LLC
Publication of AU3136293A publication Critical patent/AU3136293A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
AU31362/93A 1991-11-15 1992-11-10 Pharmaceutical tablet with pvp having an enhanced drug dissolution rate Abandoned AU3136293A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US79256291A 1991-11-15 1991-11-15
US792562 1991-11-15
US07/796,999 US5262171A (en) 1991-11-25 1991-11-25 Pharmaceutical tablet with PVP having enhanced drug dissolution rate
US796999 1991-11-25

Publications (1)

Publication Number Publication Date
AU3136293A true AU3136293A (en) 1993-06-15

Family

ID=27121299

Family Applications (1)

Application Number Title Priority Date Filing Date
AU31362/93A Abandoned AU3136293A (en) 1991-11-15 1992-11-10 Pharmaceutical tablet with pvp having an enhanced drug dissolution rate

Country Status (2)

Country Link
AU (1) AU3136293A (fr)
WO (1) WO1993009763A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1301966B1 (it) * 1998-07-30 2000-07-20 Zambon Spa Composizioni farmaceutiche ad attivita' analgesica
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
ATE537811T1 (de) † 1999-02-08 2012-01-15 Intarcia Therapeutics Inc Stabile nicht wässerige einphasige visköse vehikel und formulierungen die diese vehikel verwenden
US6761905B2 (en) 2001-05-01 2004-07-13 Wei Ming Pharmaceutical Mfg. Co., Ltd. Process for the preparation of direct tabletting formulations and aids
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
WO2006083761A2 (fr) 2005-02-03 2006-08-10 Alza Corporation Solutions de solvant/polymere utilisees comme vehicules de suspension
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
CN101453982B (zh) 2006-05-30 2011-05-04 精达制药公司 两件式内部通道渗透递送系统流动调节器
WO2008021133A2 (fr) 2006-08-09 2008-02-21 Intarcia Therapeutics, Inc. systèmes d'administration osmotiques et ensembles pistons
EP2157967B1 (fr) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Formulations en suspension de peptides insulinotropes et leurs utilisations
PL2225230T3 (pl) 2007-12-07 2017-08-31 Vertex Pharmaceuticals Incorporated Stałe postacie kwasu 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-ilo)cyklopropanokarboksyamido)-3-metylopirydyn-2-ylo)benzoesowego
EP2240155B1 (fr) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Dispositifs, formulations et méthodes d administration de plusieurs agents bénéfiques
CN104323981B (zh) 2009-09-28 2019-03-12 精达制药公司 基本稳态药物递送的快速建立和/或终止
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
WO2016196851A2 (fr) 2015-06-03 2016-12-08 Intarcia Therapeutics, Inc. Systèmes de mise en place et de retrait d'implant
MX2018014016A (es) 2016-05-16 2019-08-01 Intarcia Therapeutics Inc Polipéptidos selectivos del receptor de glucagón y métodos para utilizarlos.
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法
US10537585B2 (en) * 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4344934A (en) * 1978-11-20 1982-08-17 American Home Products Corporation Therapeutic compositions with enhanced bioavailability
US5009897A (en) * 1988-06-24 1991-04-23 Abbott Laboratories Pharmaceutical granules and tablets made therefrom
US5035897A (en) * 1989-09-05 1991-07-30 Alza Corporation Dosage form for delivering soluble or insoluble drugs

Also Published As

Publication number Publication date
WO1993009763A1 (fr) 1993-05-27

Similar Documents

Publication Publication Date Title
AU3136293A (en) Pharmaceutical tablet with pvp having an enhanced drug dissolution rate
AU2263692A (en) Multiple pharmaceutical syringe
AU6534894A (en) Drug administration system
IL101795A0 (en) Pharmaceutical tablet formulations
AU4227793A (en) Drug infuser
DE69427472D1 (de) Arzneimittel mit kontrollierter Wirkstoffabgabe
IL109661A0 (en) Drug delivery device
AU4989993A (en) Drug delivery system
AU4425789A (en) Orally pharmaceutical preparations with colon selective delivery
AU3415893A (en) Automated drug infusion system with autopriming
EP0567653A4 (en) Drug for hepatic diseases
IL101679A0 (en) Pharmaceutical tablet formulation
AU660290B2 (en) Multiple drug delivery system
AU1189392A (en) Pharmaceutical agent
ZA927506B (en) New drug formulation.
AU3144993A (en) Fluorophore-assisted therapeutic drug monitoring
AU7502194A (en) Medication administration apparatus
AU8614291A (en) Device for administering drugs
AU1797592A (en) Vaginal drug delivery device
AU3041789A (en) Pharmaceutical formulations with controlled drug release
AU1103092A (en) Immunopotentiating drug
GB2292887B (en) Drug delivery system
AU116209S (en) A pharmaceutical tablet
AU2730588A (en) Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates
CA69440S (en) Pharmaceutical tablet